Rock Samphire (Crithmum maritimum L.) as a Functional Food: Awareness, Consumption Habits and Culinary Use

Functional foods are the name given to food groups that, when consumed, have beneficial effects such as promoting and maintaining metabolic health and preventing diseases, rather than just meeting nutritional needs. Rock samphire (Crithmum maritimum L.), is a plant that grows naturally in the Mediterranean and Aegean regions of Turkey and on the coasts of Cyprus, has been consumed in these regions for many years. The consumption of the rock samphire, which draws attention with its high iodine and bioactive component content, has been limited to the regions where it grows. In this study, the local consumption habits, recipes of the rock samphire plant and the awareness of its functional properties were determined. In the study, six different recipes were obtained from the local people. Traditional products prepared according to the recipes were photographed by the authors. In addition, twenty local people were interviewed and it was determined that consumers were informed about the functional properties of the rock samphire and that these properties motivated consumers to consume the plant. As a result of the study, it was concluded that the integration of locally-consumed rock samphire into the daily diets by introducing them into non-regional cuisines would contribute positively to the general public health and the economy of the region

Trigeminal Neuralgia Associated with Vagus Nerve Stimulation: A Case Presentation and Literature Review

Vagus nerve stimulation (VNS) is an effective therapeutic option that is widely used worldwide in drug-resistant epilepsy cases. Because it is a surgical procedure, some complications may develop with VNS implantation. Although VNS-related pain symptoms have been reported, VNS-related trigeminal neuralgia is an unexpected and rather rare side effect. This report presents a case of trigeminal pain as an adverse effect of VNS. A patient with drug-resistant epilepsy undergoing VNS treatment developed pain synchronously with stimulation in his left upper and lower jaw and teeth. Pain occurred on the day of stimulation’s current intensity (SCI) increase. The sudden disappearance of pain with decreasing SCI suggested that trigeminal pain was related to VNS. Because it is a rare side effect, trigeminal pain may not be regarded as a VNS-related side effect and may lead to unnecessary examinations. Being a rapidly reversible side effect, recognizing it and reducing SCI is crucial. VNS stimulation paradigms on nociception are still largely unknown, and it will be an important step to elucidate the important impact of VNS in pain modulation

The effects of ıntravenous novacoc® treatment on metabolic profiles during the transition period of dairy cows

Sunulan çalışma süt ineklerine doğuma üç hafta kala, haftalık olarak yapılan damar içi Novacoc® enjeksiyonunun, erken laktasyon dönemde bazı kan, metabolizma ve bağışıklık parametreleri üzerine etkisini incelemek amacıyla yürütülmüştür. Çalışmada, 20 adet Holştayn ırkı süt ineği rastgele olarak kontrol ve uygulama olmak üzere iki gruba ayrılmıştır. Çalışma boyunca uygulama grubundaki ineklere, doğuma üç hafta kala başlayıp doğuma kadar devam edecek şekilde, her haftanın ilk üç günü uygulamak üzere günde 200 ml Novacoc® (Metamizol Sodyum; 40 mg, Asetilmetiyonin 40 mg, Kafein 3,5 mg, Kalsiyum Glukonat 100 mg, Magnezyum Glukonat 10 mg, Sodyum Dihidrojen Fosfat Dihidrat 4,02 mg, Glikoz monohidrat 200; İnterhas®, Türkiye) damar içi yavaş infüzyon şeklinde uygulanmıştır. Buzağılama günü “0 (sıfır)” kabul edilerek; tüm ineklerin kuyruk venasından (V.Coccygea) -21, -14, -7, 0, 7, 14, 21. günlerde hematolojik ve biyokimyasal analizler için örnekler alınmıştır. Kan total kolesterol, HDL, Trigliserit ve glukoz seviyeleri doğum sonrasında bazı günlerde istatiksel ancak tamamında sayısal olarak yüksek bulunmuş, NEFA ve BHBA seviyeleri ise düşük bulunmuştur. Öyle ki kontrol grubunun NEFA ve BHBA değerleri subklinik ketozis düzeyinde seyretmiştir. Bu verilere ek olarak laktasyonun ilk üç haftası süt verimi her iki grupta da benzer iken pik süt verimi uygulama grubunda anlamlı şekilde yüksek bulunmuştur.This study was performed to evaluate the effect of weekly intravaneous administration of Novacoc®, 3 weeks before parturition on some hematological, metabolism, and immune parameters on early lactation period in dairy cows. In this study 20 random Holstein dairy cows has been used and divided into two groups as control group and the treatment group. The treatment started 3 weeks before parturation and ended parturaiton. The treatment has been made in first three days of each week. The animals in the treatment group were administered daily Novacoc®, 200 ml (Metamizol Sodium; 40 mg, Acetyl methionine 40 mg, Caffeine 3,5 mg, Calcium Gluconate 100 mg, Magnesium Gluconate 10 mg, Sodium Dihydrogen Phospate Dhydrate 4,02 mg, Glucose monohydrate 200; İnterhas®, Türkiye) as intravenous slowly infusion on first 3 days of each weeks during last 3 weeks of prepartum period and first 3 weeks of postpartum period. Parturition day was planned as day “0 (zero)”; blood samples were collected on days -21, -14, -7, 0, 7, 14, 21 from V. Coccygea of all cows. Total cholesterol, HDL, triglyceride, and glucose levels were significantly higher on some postpartum days; However, NEFA and BHBA levels were found decreased. NEFA and BHBA levels in the control group were detected as subclinical ketosis levels. In addition to this results, the milk yields of each group were measured as same during first 3 weeks of lactation, but peak milk yield on the treatment group increased significantly

The Effects of Intravenous Novacoc® Treatment on Metabolic Profiles During the Transition Period of Dairy Cows

Sunulan çalışma süt ineklerine doğuma üç hafta kala, haftalık olarak yapılan damar içi Novacoc® enjeksiyonunun, erken laktasyon dönemde bazı kan, metabolizma ve bağışıklık parametreleri üzerine etkisini incelemek amacıyla yürütülmüştür. Çalışmada, 20 adet Holştayn ırkı süt ineği rastgele olarak kontrol ve uygulama olmak üzere iki gruba ayrılmıştır. Çalışma boyunca uygulama grubundaki ineklere, doğuma üç hafta kala başlayıp doğuma kadar devam edecek şekilde, her haftanın ilk üç günü uygulamak üzere günde 200 ml Novacoc® (Metamizol Sodyum; 40 mg, Asetilmetiyonin 40 mg, Kafein 3,5 mg, Kalsiyum Glukonat 100 mg, Magnezyum Glukonat 10 mg, Sodyum Dihidrojen Fosfat Dihidrat 4,02 mg, Glikoz monohidrat 200; İnterhas®, Türkiye) damar içi yavaş infüzyon şeklinde uygulanmıştır. Buzağılama günü "0 (sıfır)" kabul edilerek; tüm ineklerin kuyruk venasından (V.Coccygea) -21, -14, -7, 0, 7, 14, 21. günlerde hematolojik ve biyokimyasal analizler için örnekler alınmıştır. Kan total kolesterol, HDL, Trigliserit ve glukoz seviyeleri doğum sonrasında bazı günlerde istatiksel ancak tamamında sayısal olarak yüksek bulunmuş, NEFA ve BHBA seviyeleri ise düşük bulunmuştur. Öyle ki kontrol grubunun NEFA ve BHBA değerleri subklinik ketozis düzeyinde seyretmiştir. Bu verilere ek olarak laktasyonun ilk üç haftası süt verimi her iki grupta da benzer iken pik süt verimi uygulama grubunda anlamlı şekilde yüksek bulunmuşturThis study was performed to evaluate the effect of weekly intravaneous administration of Novacoc®, 3 weeks before parturition on some hematological, metabolism, and immune parameters on early lactation period in dairy cows. In this study 20 random Holstein dairy cows has been used and divided into two groups as control group and the treatment group. The treatment started 3 weeks before parturation and ended parturaiton. The treatment has been made in first three days of each week. The animals in the treatment group were administered daily Novacoc®, 200 ml (Metamizol Sodium; 40 mg, Acetyl methionine 40 mg, Caffeine 3,5 mg, Calcium Gluconate 100 mg, Magnesium Gluconate 10 mg, Sodium Dihydrogen Phospate Dhydrate 4,02 mg, Glucose monohydrate 200; İnterhas®, Türkiye) as intravenous slowly infusion on first 3 days of each weeks during last 3 weeks of prepartum period and first 3 weeks of postpartum period. Parturition day was planned as day “0 (zero)”; blood samples were collected on days -21, -14, -7, 0, 7, 14, 21 from V. Coccygea of all cows. Total cholesterol, HDL, triglyceride, and glucose levels were significantly higher on some postpartum days; However, NEFA and BHBA levels were found decreased. NEFA and BHBA levels in the control group were detected as subclinical ketosis levels. In addition to this results, the milk yields of each group were measured as same during first 3 weeks of lactation, but peak milk yield on the treatment group increased significantl

Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Background: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH.Fil: Efe, Cumali. Harran University Hospita; TurquíaFil: Lammert, Craig. University School of Medicine Indianapolis; Estados UnidosFil: Taşçılar, Koray. Universitat Erlangen-Nuremberg; AlemaniaFil: Dhanasekaran, Renumathy. University of Stanford; Estados UnidosFil: Ebik, Berat. Gazi Yasargil Education And Research Hospital; TurquíaFil: Higuera de la Tijera, Fatima. Hospital General de México; MéxicoFil: Calışkan, Ali R.. No especifíca;Fil: Peralta, Mirta. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; ArgentinaFil: Gerussi, Alessio. Università degli Studi di Milano; ItaliaFil: Massoumi, Hatef. No especifíca;Fil: Catana, Andreea M.. Harvard Medical School; Estados UnidosFil: Purnak, Tugrul. University of Texas; Estados UnidosFil: Rigamonti, Cristina. Università del Piemonte Orientale ; ItaliaFil: Aldana, Andres J. G.. Fundacion Santa Fe de Bogota; ColombiaFil: Khakoo, Nidah. Miami University; Estados UnidosFil: Nazal, Leyla. Clinica Las Condes; ChileFil: Frager, Shalom. Montefiore Medical Center; Estados UnidosFil: Demir, Nurhan. Haseki Training And Research Hospital; TurquíaFil: Irak, Kader. Kanuni Sultan Suleyman Training And Research Hospital; TurquíaFil: Melekoğlu Ellik, Zeynep. Ankara University Medical Faculty; TurquíaFil: Kacmaz, Hüseyin. Adıyaman University; TurquíaFil: Balaban, Yasemin. Hacettepe University; TurquíaFil: Atay, Kadri. No especifíca;Fil: Eren, Fatih. No especifíca;Fil: Alvares da-Silva, Mario R.. Universidade Federal do Rio Grande do Sul; BrasilFil: Cristoferi, Laura. Università degli Studi di Milano; ItaliaFil: Urzua, Álvaro. Universidad de Chile; ChileFil: Eşkazan, Tuğçe. Cerrahpaşa School of Medicine; TurquíaFil: Magro, Bianca. No especifíca;Fil: Snijders, Romee. No especifíca;Fil: Barutçu, Sezgin. No especifíca;Fil: Lytvyak, Ellina. University of Alberta; CanadáFil: Zazueta, Godolfino M.. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Demirezer Bolat, Aylin. Ankara City Hospital; TurquíaFil: Aydın, Mesut. Van Yuzuncu Yil University; TurquíaFil: Amorós Martín, Alexandra Noemí. No especifíca;Fil: De Martin, Eleonora. No especifíca;Fil: Ekin, Nazım. No especifíca;Fil: Yıldırım, Sümeyra. No especifíca;Fil: Yavuz, Ahmet. No especifíca;Fil: Bıyık, Murat. Necmettin Erbakan University; TurquíaFil: Narro, Graciela C.. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Bıyık, Murat. Uludag University; TurquíaFil: Kıyıcı, Murat. No especifíca;Fil: Kahramanoğlu Aksoy, Evrim. No especifíca;Fil: Vincent, Maria. No especifíca;Fil: Carr, Rotonya M.. University of Pennsylvania; Estados UnidosFil: Günşar, Fulya. No especifíca;Fil: Reyes, Eira C.. Hepatology Unit. Hospital Militar Central de México; MéxicoFil: Harputluoğlu, Murat. Inönü University School of Medicine; TurquíaFil: Aloman, Costica. Rush University Medical Center; Estados UnidosFil: Gatselis, Nikolaos K.. University Hospital Of Larissa; GreciaFil: Üstündağ, Yücel. No especifíca;Fil: Brahm, Javier. Clinica Las Condes; ChileFil: Vargas, Nataly C. E.. Hospital Nacional Almanzor Aguinaga Asenjo; PerúFil: Güzelbulut, Fatih. No especifíca;Fil: Garcia, Sandro R.. Hospital Iv Víctor Lazarte Echegaray; PerúFil: Aguirre, Jonathan. Hospital Angeles del Pedregal; MéxicoFil: Anders, Margarita. Hospital Alemán; ArgentinaFil: Ratusnu, Natalia. Hospital Regional de Ushuaia; ArgentinaFil: Hatemi, Ibrahim. No especifíca;Fil: Mendizabal, Manuel. Universidad Austral; ArgentinaFil: Floreani, Annarosa. Università di Padova; ItaliaFil: Fagiuoli, Stefano. No especifíca;Fil: Silva, Marcelo. Universidad Austral; ArgentinaFil: Idilman, Ramazan. No especifíca;Fil: Satapathy, Sanjaya K.. No especifíca;Fil: Silveira, Marina. University of Yale. School of Medicine; Estados UnidosFil: Drenth, Joost P. H.. No especifíca;Fil: Dalekos, George N.. No especifíca;Fil: N.Assis, David. University of Yale. School of Medicine; Estados UnidosFil: Björnsson, Einar. No especifíca;Fil: Boyer, James L.. University of Yale. School of Medicine; Estados UnidosFil: Yoshida, Eric M.. University of British Columbia; CanadáFil: Invernizzi, Pietro. Università degli Studi di Milano; ItaliaFil: Levy, Cynthia. University of Miami; Estados UnidosFil: Montano Loza, Aldo J.. University of Alberta; CanadáFil: Schiano, Thomas D.. No especifíca;Fil: Ridruejo, Ezequiel. Universidad Austral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Wahlin, Staffan. No especifíca

The Impact of COVID-19 Outbreak On Quality of Life, Seizure Frequency, Depression, and Anxiety in Patients with Epilepsy: A Cross-Sectional Study During the Early Period

INTRODUCTION:Epilepsy, according to our current knowledge, does not increase the risk of Coronavirus disease 2019 (COVID-19) infection or the rate of complications related to this infection. However, the COVID-19 pandemic can have adverse effects on patients with epilepsy (PWE) and affect the mental health of the community in general. This study aimed to evaluate the depression and anxiety of epilepsy patients, the effect of the epidemic on the frequency of seizures, and the quality of life of the patients in the past 3 months during the pandemic.METHODS:The patients who were referred to an epilepsy outpatient clinic of a tertiary neuropsychiatry center within the past 2 years were retrospectively evaluated. The data regarding the seizures, quality of life, anxiety, and depression were recorded during follow-up or through an online platform. Seizure frequency, frequency change during the pandemic (April 2020 to June 2020), medications, admissions were obtained, and Beck Depression and Anxiety Scale were applied to the patients. The patients’ quality of life was evaluated using the “Quality of Life Scale Short Form-36 (SF-36)” form.RESULTS:One hundred sixty-four patients (77 men, 87 women) included in the study were analyzed. The median overall seizure frequency and seizure frequency during pandemic were 0.2 seizures/month (0–1) and 0 seizures/month (0–0.9), respectively. 125(76.2%) of the patients reported that they had no seizures during that period. No significant difference was found between the frequency of seizures reported by the patients before and during the pandemic period (p=0.12). Only one patient had a PCR confirmed COVID-19 diagnosis, and the other six patients were diagnosed clinically and radiologically. No significant relationship was found between COVID-19 diagnosis and seizure frequency (p=0.671). 105(64.02%) patients were considered to have depressive symptoms with ten or more points according to the Beck Depression Scale. 116 patients (70.7%) were considered to have anxiety symptoms with nine or more points from the Beck Anxiety Scale.DISCUSSION AND CONCLUSION:This study was conducted to evaluate the seizure frequency, psychiatric status, and quality of life of PWE in April, May, and June 2020 during the first peak of the COVID-19 pandemic in our country while the social restrictions were applied at the highest level. We found that there was no significant increase in the seizure frequency of patients during the pandemic period and depressive symptoms were common in this patient group and affected their quality of life

Parking as a loss leader at shopping malls

This paper investigates the pricing of malls in an environment where shoppers choose between a car and public transportation in getting to a suburban mall. The mall implicitly engages in mixed bundling; it sells goods bundled with parking to shoppers who come by car, and only goods to shoppers who come by public transportation. There are external costs of discomfort in public transportation due to crowdedness. Thus, shoppers using public transportation deter each other. The mall internalizes these external costs, much like a policy maker. To do so, it raises the sales price of the good and sets a parking fee less than parking’s marginal cost. Hence, parking is always a loss leader. Surprisingly, this pricing scheme is not necessarily distortionary

Vacuolating Megalencephalic Leukoencephalopathy with Subcortical Cysts (Van der Knaap Leukoencephalopathy): A Case Diagnosed in Adulthood

Van der Knaap leukoencephalopathy is a rare vacuolating megalencephalic leukoencephalopathy with subcortical cysts. It is inherited autosomal recessively with MLC1 and GlialCAM mutations. The disease is usually diagnosed in the patient's first years of childhood and symptoms are severe in adulthood. In this case, a male patient aged 35 years presented with pathologic cerebellar and pyramidal findings. Magnetic resonance imaging revealed bilateral cystic degeneration in the anterior temporal lobes, swelling in the supratentorial white matter, and abnormal signal. There were no pathologic findings in the differential diagnosis tests. The patient was diagnosed as having Van der Knaap leukoencephalopathy according to the clinical and radiologic findings